|
1
|
Siegel RL, Kratzer TB, Giaquinto AN, Sung
H and Jemal A: Cancer statistics, 2025. CA Cancer J Clin. 75:10–45.
2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Goldman JW, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab, with or without tremelimumab, plus
platinum-etoposide versus platinum-etoposide alone in first-line
treatment of extensive-stage small-cell lung cancer (CASPIAN):
Updated results from a randomised, controlled, open-label, phase 3
trial. Lancet Oncol. 22:51–65. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lee JH, Saxena A and Giaccone G:
Advancements in small cell lung cancer. Semin Cancer Biol.
93:123–128. 2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Zhu Y, Liu K, Zhu H, Cao H and Zhou Y:
Comparative efficacy and safety of novel immuno-chemotherapy for
extensive-stage small-cell lung cancer: A network meta-analysis of
randomized controlled trial. Ther Adv Med Oncol: Oct 14, 2023 (Epub
ahead of print).
|
|
5
|
Sabari JK, Lok BH, Laird JH, Poirier JT
and Rudin CM: Unravelling the biology of SCLC: Implications for
therapy. Nat Rev Clin Oncol. 14:549–561. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
National Comprehensive Cancer Network.
NCCN Clinical Practice Guidelines in Oncology: Small Cell Lung
Cancer.Version 2.2026. Accessed March 2026. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461.
|
|
7
|
Kapugi M and Cunningham K:
Corticosteroids. Orthop Nurs. 38:336–339. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Li N, Zheng X, Gan J, Zhuo T, Li X, Yang
C, Wu Y and Qin S: Effects of glucocorticoid use on survival of
advanced non-small-cell lung cancer patients treated with immune
checkpoint inhibitors. Chin Med J (Engl). 136:2562–2572.
2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Hesketh PJ, Kris MG, Basch E, Bohlke K,
Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina
SB, et al: Antiemetics: ASCO guideline update. J Clin Oncol.
38:2782–2797. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Freites-Martinez A, Santana N,
Arias-Santiago S and Viera A: Using the common terminology criteria
for adverse events (CTCAE-Version 5.0) to evaluate the severity of
adverse events of anticancer therapies. Actas Dermosifiliogr (Engl
Ed). 112:90–92. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Schwartz LH, Litiere S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Kalfeist L, Galland L, Ledys F,
Ghiringhelli F, Limagne E and Ladoire S: Impact of glucocorticoid
use in oncology in the immunotherapy era. Cells.
11(770)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Cruz-Topete D and Cidlowski JA: One
hormone, two actions: Anti- and pro-inflammatory effects of
glucocorticoids. Neuroimmunomodulation. 22:20–32. 2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Busillo JM and Cidlowski JA: The five Rs
of glucocorticoid action during inflammation: Ready, reinforce,
repress, resolve, and restore. Trends Endocrinol Metab. 24:109–119.
2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pofi R, Caratti G, Ray DW and Tomlinson
JW: Treating the side effects of exogenous glucocorticoids; can we
separate the good from the bad? Endocr Rev. 44:975–1011.
2023.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Zhong W, Shahbaz O, Teskey G, Beever A,
Kachour N, Venketaraman V and Darmani NA: Mechanisms of nausea and
vomiting: Current knowledge and recent advances in intracellular
emetic signaling systems. Int J Mol Sci. 22(5797)2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Reichardt SD, Amouret A, Muzzi C,
Vettorazzi S, Tuckermann JP, Luhder F and Reichardt HM: The role of
glucocorticoids in inflammatory diseases. Cells.
10(2921)2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Cain DW and Cidlowski JA: Immune
regulation by glucocorticoids. Nat Rev Immunol. 17:233–247.
2017.
|
|
19
|
Li D, Yang M, Zhang J, Zhong J, Ding H,
Chen W, Pan J and Liao J: Development and validation of nomogram
for predicting the risk of community-acquired pneumonia after
kidney transplantation of deceased donors. Life Conflux.
1(e115)2025.
|
|
20
|
Choi HM, Jo SK, Kim SH, Lee JW, Cho E,
Hyun YY, Cha JJ, Kang YS, Cha DR, Cho WY and Kim HK:
Glucocorticoids attenuate septic acute kidney injury. Biochem
Biophys Res Commun. 435:678–684. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Horie S, Oya M, Nangaku M, Yasuda Y,
Komatsu Y, Yanagita M, Kitagawa Y, Kuwano H, Nishiyama H, Ishioka
C, et al: Guidelines for treatment of renal injury during cancer
chemotherapy 2016. Clin Exp Nephrol. 22:210–244. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ricciuti B, Dahlberg SE, Adeni A, Sholl
LM, Nishino M and Awad MM: Immune checkpoint inhibitor outcomes for
patients with non-small-cell lung cancer receiving baseline
corticosteroids for palliative versus nonpalliative indications. J
Clin Oncol. 37:1927–1934. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Schneider BJ, Naidoo J, Santomasso BD,
Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino
JM, Chau I, et al: Management of immune-related adverse events in
patients treated with immune checkpoint inhibitor therapy: ASCO
guideline update. J Clin Oncol. 39:4073–4126. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Goodwin JE and Geller DS:
Glucocorticoid-induced hypertension. Pediatr Nephrol. 27:1059–1066.
2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Hoes JN, van der Goes MC, van Raalte DH,
van der Zijl NJ, den Uyl D, Lems WF, Lafeber FP, Jacobs JWJ,
Welsing PMJ, Diamant M and Bijlsma JWJ: Glucose tolerance, insulin
sensitivity and beta-cell function in patients with rheumatoid
arthritis treated with or without low-to-medium dose
glucocorticoids. Ann Rheum Dis. 70:1887–1894. 2011.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lakhani OJ, Kumar S, Tripathi S, Desai M
and Seth C: Comparison of two protocols in the management of
glucocorticoid-induced hyperglycemia among hospitalized patients.
Indian J Endocrinol Metab. 21:836–844. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Struja T, Nitritz N, Alexander I,
Kupferschmid K, Hafner JF, Spagnuolo CC, Schuetz P, Mueller B and
Blum CA: Treatment of glucocorticoid- induced hyperglycemia in
hospitalized patients-a systematic review and meta- analysis. Clin
Diabetes Endocrinol. 10(8)2024.PubMed/NCBI View Article : Google Scholar
|
